2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy
Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53: 1461-1468. PMID: 22260160, PMCID: PMC7845767, DOI: 10.3109/10428194.2012.658793.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleGeriatricsHumansLymphoma, Large B-Cell, DiffuseMaleMedical OncologyMiddle AgedPrednisoneRemission InductionRetrospective StudiesRituximabTreatment OutcomeVincristineConceptsNon-Hodgkin lymphomaLarge cell lymphomaCell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaChemotherapy dose reductionsTreatment-related toxicityR-CHOP treatmentSingle-institution studyB-cell lymphomaCurative intentRelative chemotherapyComplete remissionPrimary therapyElderly patientsSupportive careTreatment toxicityAged patientsPatient populationTreatment outcomesRetrospective analysisDose reductionElderly populationPatientsLymphoma
2010
Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy
Huntington S, Sharifi M, Greer J, Morgan D, Reddy N. Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy. Blood 2010, 116: 1778. DOI: 10.1182/blood.v116.21.1778.1778.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaRelative dose intensityInternational Prognostic IndexBody surface areaCumulative Illness Rating ScaleLarge B-cell lymphomaB-cell lymphomaDose intensityElderly patientsDose reductionAge groupsPerformance statusComplete responseMedian ageAged patientsDisease stageLDH levelsAge-adjusted International Prognostic IndexAverage relative dose intensityProphylactic colony-stimulating factorsDiagnosis of DLBCLMultivariate logistic regression analysisTreatment of DLBCLMultivariate logistic regression modelingElectronic medical record database